BR102018016746A8 - Composição farmacêutica para prevenção de obesidade induzida por dieta - Google Patents

Composição farmacêutica para prevenção de obesidade induzida por dieta

Info

Publication number
BR102018016746A8
BR102018016746A8 BR102018016746A BR102018016746A BR102018016746A8 BR 102018016746 A8 BR102018016746 A8 BR 102018016746A8 BR 102018016746 A BR102018016746 A BR 102018016746A BR 102018016746 A BR102018016746 A BR 102018016746A BR 102018016746 A8 BR102018016746 A8 BR 102018016746A8
Authority
BR
Brazil
Prior art keywords
diet
prevention
pharmaceutical composition
obesity
induced obesity
Prior art date
Application number
BR102018016746A
Other languages
English (en)
Other versions
BR102018016746A2 (pt
Inventor
Ankit Shyam Singh
Vedprakash Mishra
Neelima Tongra
Original Assignee
Frimline Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frimline Private Ltd filed Critical Frimline Private Ltd
Publication of BR102018016746A2 publication Critical patent/BR102018016746A2/pt
Publication of BR102018016746A8 publication Critical patent/BR102018016746A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

COMPOSIÇÃO FARMACÊUTICA PARA PREVENÇÃO DE OBESIDADE INDUZIDA POR DIETA. Composição/formulação farmacêutica para a prevenção de obesidade induzida por dieta. Mais particularmente, a invenção se refere a uma composição/formulação que compreende uma combinação sinérgica de Oleoiletanolamida (OEA) e outros ingredientes naturais que pode ser usada para tratamento de obesidade e seus distúrbios relacionados associados ao metabolismo de gordura tipo esteato-hepatite não alcoólica (NASH), doença hepática gordurosa não alcoólica (NAFLD). A mesma pode também ser útil no controle de obesidade por meio da manutenção do peso corporal. A invenção fornece também várias formulações e métodos de preparo da mesma.
BR102018016746A 2017-08-19 2018-08-16 Composição farmacêutica para prevenção de obesidade induzida por dieta BR102018016746A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201721029447 2017-08-19
IN201721029447 2017-08-19

Publications (2)

Publication Number Publication Date
BR102018016746A2 BR102018016746A2 (pt) 2019-03-26
BR102018016746A8 true BR102018016746A8 (pt) 2023-02-14

Family

ID=63244444

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102018016746A BR102018016746A8 (pt) 2017-08-19 2018-08-16 Composição farmacêutica para prevenção de obesidade induzida por dieta

Country Status (19)

Country Link
US (1) US10702487B2 (pt)
EP (1) EP3443987B1 (pt)
BR (1) BR102018016746A8 (pt)
CA (1) CA3012675C (pt)
CY (1) CY1124010T1 (pt)
DK (1) DK3443987T3 (pt)
EA (1) EA201891651A3 (pt)
ES (1) ES2864136T3 (pt)
HR (1) HRP20210466T1 (pt)
HU (1) HUE053678T2 (pt)
LT (1) LT3443987T (pt)
MY (1) MY177974A (pt)
PH (1) PH12018000207B1 (pt)
PL (1) PL3443987T3 (pt)
PT (1) PT3443987T (pt)
RS (1) RS61628B1 (pt)
SG (1) SG10201806472SA (pt)
SI (1) SI3443987T1 (pt)
UA (1) UA122710C2 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021041495A2 (en) * 2019-08-26 2021-03-04 The Trustees Of Indiana University Method to maintain or enhance tissue
CN111084301B (zh) * 2019-12-30 2023-08-22 内江师范学院 一种桑叶提取物鱼饲料粘合剂及制备方法和应用
CN113712206A (zh) * 2021-09-16 2021-11-30 湖南希尔天然药业有限公司 一种含有桑叶dnj和桑叶肽的组合物及其制备方法
AU2022416432A1 (en) * 2021-12-13 2024-07-25 The Regents Of The University Of California Method of treating liver steatosis with bioavailable formulation of oleoylethanolamide
WO2023250211A2 (en) * 2022-06-24 2023-12-28 Veroscience Llc Treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042687A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of treating obesity by the oral administration of a predigested protein composition
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
WO2002080860A2 (en) 2001-03-27 2002-10-17 The Regents Of The University Of California Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
AU2003296895A1 (en) 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
AU2003290387A1 (en) 2002-11-18 2004-06-15 Natural Asa Dietry supplements and foods product comprising oleylethanolamide
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
EP1677780A4 (en) 2003-10-16 2007-05-02 Univ California DIETETIC COMPOSITIONS AND OTHER COMPOSITIONS, COMPOUNDS AND METHODS FOR ORGANIC LIPID REDUCTION, APPETILE CONTROL, AND METABOLISM MODULATION OF FATTY ACIDS
EP1917007A2 (en) 2005-07-14 2008-05-07 Rheoscience A/S Inhibitors of anorexic lipid hydrolysis for the treatment of eating disorders
JP5388602B2 (ja) * 2008-01-25 2014-01-15 小林製薬株式会社 抗肥満用医薬組成物
JP2011521914A (ja) 2008-05-19 2011-07-28 ネステク ソシエテ アノニム 動物による脂質吸収を抑制する方法
US9187413B2 (en) 2010-07-28 2015-11-17 The Regents Of The University Of California Peripherally restricted FAAH inhibitors
WO2012090225A2 (en) 2010-12-29 2012-07-05 Nutracryst Therapeutics Private Limited Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
WO2012154711A1 (en) 2011-05-10 2012-11-15 Nestec S.A. Methods and compositions for promoting lean body mass growth
MX354772B (es) 2011-08-19 2018-03-21 Univ California Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.
CN102579414A (zh) 2012-01-29 2012-07-18 厦门大学 油酰乙醇胺作为降血脂、防治非酒精性脂肪肝药物的用途
ES2667056T3 (es) 2012-07-24 2018-05-09 Bial-Portela & Ca, S.A. Compuestos de urea y su uso como inhibidores enzimáticos
WO2014037546A1 (en) 2012-09-07 2014-03-13 Nestec S.A. Oleoylethanolamide compositions
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
WO2015007615A1 (en) 2013-07-18 2015-01-22 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
LT3024825T (lt) 2013-07-24 2017-12-11 Bial - Portela & C, S.A. Imidazolo karboksamidai ir jų panaudojimas kaip faah inhibitorių
BR112016002196A2 (pt) 2013-08-01 2017-08-01 BIAL PORTELA & Cª S A compostos de ureia e sua utilização como inibidores enzimáticos
ES2908240T3 (es) 2014-04-07 2022-04-28 Univ California Inhibidores de la enzima amida hidrolasa de ácidos grasos (FAAH) con biodisponibilidad oral mejorada y su uso como medicamentos
US20180116982A1 (en) 2015-05-21 2018-05-03 Therapix Biosciences Ltd. Combinations of opioids and n-acylethanolamines
RU2737893C2 (ru) 2015-08-11 2020-12-04 Айсью Медсинз Б.В. Пэгилированная липидная наночастица с биоактивным липофильным соединением

Also Published As

Publication number Publication date
EP3443987B1 (en) 2020-12-23
MY177974A (en) 2020-09-28
EP3443987A1 (en) 2019-02-20
PL3443987T3 (pl) 2021-08-02
CA3012675C (en) 2021-06-15
EA201891651A3 (ru) 2019-05-31
US20190054046A1 (en) 2019-02-21
UA122710C2 (uk) 2020-12-28
PH12018000207A1 (en) 2019-06-03
ES2864136T3 (es) 2021-10-13
PH12018000207B1 (en) 2019-06-03
RS61628B1 (sr) 2021-04-29
EA201891651A2 (ru) 2019-02-28
US10702487B2 (en) 2020-07-07
CY1124010T1 (el) 2022-05-27
SG10201806472SA (en) 2019-03-28
PT3443987T (pt) 2021-03-18
SI3443987T1 (sl) 2021-07-30
CA3012675A1 (en) 2019-02-19
HRP20210466T1 (hr) 2021-05-14
LT3443987T (lt) 2021-04-26
HUE053678T2 (hu) 2021-07-28
BR102018016746A2 (pt) 2019-03-26
DK3443987T3 (da) 2021-03-22

Similar Documents

Publication Publication Date Title
BR102018016746A8 (pt) Composição farmacêutica para prevenção de obesidade induzida por dieta
BRPI0819690B8 (pt) uso de uma composição compreendendo cisteamina ou cistamina, ou um sal farmaceuticamente aceitável das mesmas
PH12017502181A1 (en) Nutritional compositions containing an elevated level of inositol and uses thereof
BR112014006220A2 (pt) composições de galacto-ramnogalacturonato para o tratamento de esteatohepatite não alcoólica e de doença de gordura no fígado não alcoólica
BR112017016766A2 (pt) composições farmacêuticas para terapia de combinação
BR112016021985A8 (pt) formulação farmacêutica e composto
CO2020010193A2 (es) Una composición farmacéutica para la anemia
BR112018072064B8 (pt) Uso de triglicerídeos de cadeia média para preparação de composições nutricionais para proteção cardíaca em animais de estimação
BR112018013227A2 (pt) ?composições farmacêuticas ou kit para o uso, métodos para tratar câncer em um mamífero e uso de uma composição?
BR112018008186A2 (pt) métodos que utilizam proteína de soro de leite para melhorar ou manter a qualidade muscular
BR112018000242A2 (pt) composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico
MX2022012079A (es) Metodos y composiciones para mantener la salud renal.
BR112017006416A2 (pt) composição nutricional para meio gastrointestinal para proporcionar perfil aperfeiçoado de microbioma e metabólico
BR112018000236A2 (pt) composições nutricionais e métodos para a promoção do desenvolvimento cognitivo
EA201592003A1 (ru) Микропищевые добавки для иммунитета
BR112015029897A2 (pt) composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição
BR112018013501A2 (pt) uso de um ingrediente fermentado e oligossacarídeo não digerível na manufatura de uma composição nutricional, método para aumento de secreção de imunoglobulina a em um indivíduo humano com idade de 0 a 36 e método para melhorar a defesa imunológica da mucosa em um indivíduo humano com idade de 0 a 36 meses
CO2017005131A2 (es) Métodos y composiciones para el incremento de la masa corporal magra y minimizar la ganancia de grasa corporal y el control del peso
MY186286A (en) A pharmaceutical composition for improving or preventing progression of chronic kidney disease
BR112015018216A2 (pt) composição do alimento e seu uso
BR112022008095A2 (pt) Métodos e composições para o tratamento da síndrome de rett
WO2018078599A3 (en) Composition for the preventive or curative treatment of liver disorders
BR112015021781A2 (pt) alta dose única de mva induz uma resposta imune protetora em neonatos e lactentes
ECSP20044715A (es) Una composición farmacéutica para la anemia
BR112017006778A2 (pt) composição farmacêutica que compreende aspirina, metformina e serotonina com tensoativo não iônico

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B03H Publication of an application: rectification [chapter 3.8 patent gazette]

Free format text: REFERENTE A RPI 2516 DE 26/03/2019, QUANTO AO ITEM 30.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06J Correction of requirement [chapter 6.10 patent gazette]

Free format text: O PRESENTE PEDIDO TEVE UMA PARECER DE EXIGENCIA NOTIFICADO NA RPI NO 2774 DE 05/03/2024, TENDO SIDO CONSTATADO QUE ESTA NOTIFICACAO FOI EFETUADA COM INCORRECOES (ERRO DE DIGITACAO NA CONCLUSAO DA EXIGENCIA), ASSIM REPUBLICO A REFERIDA PUBLICACAO.

B09A Decision: intention to grant [chapter 9.1 patent gazette]